Company news

Karyopharm Therapeutics Inc. news in 2024

Karyopharm Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.

View company

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

December 8, 2024

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

December 2, 2024

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

November 24, 2024

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

November 19, 2024

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

November 17, 2024

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

November 4, 2024

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

October 30, 2024

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

October 30, 2024

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

October 29, 2024

Karyopharm to Participate at Upcoming Investor Conferences

September 2, 2024

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

August 5, 2024

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

July 30, 2024

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 31, 2024

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 28, 2024

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 7, 2024

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 7, 2024

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

May 1, 2024

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

April 23, 2024

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

March 5, 2024

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

February 28, 2024

Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024

February 21, 2024

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

January 7, 2024

Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024